- Home
- FRPH vs XFOR Comparison
FRPH vs XFOR Comparison
Compare FRPH & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRPH | XFOR |
|---|---|---|
| Founded | 1986 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 420.6M | 377.3M |
| IPO Year | 1995 | 2017 |
Fundamental Metrics
Financial Performance| Metric | FRPH | XFOR |
|---|---|---|
| Price | $22.14 | $4.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 95.7K | ★ 689.6K |
| Earning Date | 04-10-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $42,846,000.00 | $6,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 2.57 | ★ 150.00 |
| 52 Week Low | $20.53 | $2.80 |
| 52 Week High | $26.32 | $4.83 |
Technical Indicators
Market Signals| Indicator | FRPH | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 51.09 | 50.17 |
| Support Level | $21.92 | $3.58 |
| Resistance Level | $24.57 | $4.51 |
| Average True Range (ATR) | 0.54 | 0.26 |
| MACD | 0.15 | -0.02 |
| Stochastic Oscillator | 66.09 | 21.59 |
Price Performance
Historical ComparisonAbout FRPH FRP Holdings Inc.
FRP Holdings Inc is a holding company engaged in various real estate businesses. The company's business segments are Leasing and management of commercial properties owned by the company (the Industrial/Commercial Segment); Leasing and management of mining royalty land owned by the company (the Mining Royalty Lands Segment); real property acquisition, entitlement, development and construction for apartment, retail, industrial, and office (the Development Segment), and (iv) management of mixed-use residential/retail properties owned through joint ventures.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.